Vancouver company launches new superbug test

Kent, Heather
September 1999
CMAJ: Canadian Medical Association Journal;9/21/99, Vol. 161 Issue 6, p679
Academic Journal
Reports about a test for detecting methicillin-resistant Staphylococcus aureus (MRSA) from the Canadian company I.D. Biomedical Corporation. Test approval by the United States Food and Drug Administration and expected approval by Health Canada; Comments by the Dr. Tony Holler, the company's president, about the speed and accuracy of the test; Preparation of I.D. Biomedical for a test to detect vancomycin-resistant enterococci bacteria.


Related Articles

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Flu Vaccine Debacle Bonanza for Biotech Newcomers.  // BioPharm International;Dec2004, Vol. 17 Issue 12, p10 

    The article presents information on flu vaccine bonanza, that opened doors for many biotech newcomers to enter in the market. After Food and Drug Administration (FDA) approved its noneedle inoculation product "FluMist" in June 2003, Medlmmune and its partner, Wyeth, anticipated selling three to...

  • ID BIOMEDICAL GETS NIH GRANT FOR INTRANASAL PLAGUE VACCINE.  // Biotech Business;Nov2004, Vol. 17 Issue 11, p1 

    Reports on the research grant received by Bothell, Washington-based ID Biomedical from the U.S. National Institutes of Health. Vaccine to be developed by the company with the use of the grant; Remarks from company president Todd Patrick regarding the grant received by the firm; Background of...

  • ID Biomedical to acquire Shire Pharmaceuticals vaccine business.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports on the acquisition of the vaccine business of Shire Pharmaceuticals by ID Biomedical Corp. Total amount of the deal; Services of ID; Details on the marketing of vaccines.

  • show case.  // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p19 

    The article offers information on several drugs that were approved by the U.S. Food & Drug Administration including the H5N1 avian influenza vaccine from ID Biomedical Corp., the Raltegravir from Merck, and the Telmisartan immediate-release tablet angiotension II receptor blocker from Actavis.

  • ID BIOMEDICAL INITIATES STREPTAVAX CLINICAL TRIAL.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p1 

    No abstract available.

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • Staphylococcal Toxic Shock Syndrome Caused by Tampon Use. McDermott, Cian; Sheridan, Michael // Case Reports in Critical Care;1/26/2015, Vol. 2015, p1 

    The authors report a case of near-fatal sepsis with multiorgan failure resulting from a Staphylococcal tampon-associated toxic shock syndrome, requiring a lengthy critical care admission. Successful treatment of this condition focuses on early identification, source control, and administration...

  • New products.  // Drug Topics;Oct2012, Vol. 156 Issue 10, p61 

    The article informs on various drugs and related products who have received approval from the Food & Drug Administration (FDA) in the U.S. It is mentioned that the FDA has approved the 2012-2013 influenza (flu) vaccine formulation of CSL Ltd., ID Biomedical Corp. and Sanofi Pasteur. Also,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics